A Quick Look at Using Meningococcal Conjugate Vaccines
For Persons Aged 11 Years and Older

Age Indications for MenACWY Vaccines (MCV4)
Menveo® (MenACWY-CRM): for ages 2 months through 55 years
Menactra® (MenACWY-D): for ages 9 months through 55 years

Indications for Use and Schedule
• Routinely administer:
  - One dose at aged 11-12 years; 2nd dose at age 16 years
  - Preferred for ages 56 years & older who previously received MenACWY or who are recommended to receive multiple doses of meningococcal vaccine*
• Adolescent catch-up schedule:
  - If 1st dose given at aged 13 through 15 years, give a 2nd dose at aged 16 through 18 years
  - If 1st dose given at age 16 years or older, a 2nd dose is not recommended
• Minimum interval
  - 8 weeks between 2 doses

Vaccine Administration
• Intramuscular (IM) injection in the deltoid of the arm
  - 1-1.5 inch, 22-25 gauge needle
• Use professional judgment in selecting needle length
• Give simultaneously with all vaccines with this exception:
  - If using Menactra for asplenic persons, ensure PCV13 is given first and then Menactra at least 4 weeks later

Storage and Handling
• Store in the refrigerator between 35º-46º F (2º-8º C)
• Do not freeze vaccine; Keep in the original box
• Menactra is ready to use; shake well
• Menveo must be reconstituted
  - Draw up MenCYW liquid (diluent)
  - Add to Men A vial; invert and shake well
• Administer vaccines immediately after drawn up in syringe

*PERSONS WITH CERTAIN MEDICAL OR OTHER RISK CONDITIONS
• Persons aged 11 years & older with persistent terminal complement deficiency or asplenia (functional or anatomic):
  - 2-dose primary series (0, 2 months) & a booster dose every 5 years thereafter
• Persons aged 11 years & older who are at increased risk due to prolonged exposure (e.g., travel to/living in endemic areas, current outbreak, microbiologists exposed to N. meningitidis) or when required (e.g., military recruits, travel to Mecca during annual Hajj):
  - Give 1 dose; if the person remains at increased risk, a booster dose is recommended 5 years later
• Persons with HIV and an indication for vaccination should receive a 2-dose primary series (0, 2 months)
• Need and interval for booster dose determined by risk factor
• HIV without another risk factor present is not a medical indication for meningococcal vaccination
• Ensure students age 21 years or younger who are entering college/living in dorm have received a dose in the last 5 years
  - Consider 1 dose of MenACWY for students age 21 years or younger & currently attending college, with no dose in the last 5 years
  - MenACWY is not routinely recommended for healthy persons age 22 years or older

CONTRAINDICATIONS
• An anaphylactic (severe allergic) reaction to a prior dose or a component of MenACWY vaccine

PRECAUTIONS
• Moderate to severe acute illness with or without a fever

FURTHER POINTS
• Persons indicated for a 2-dose primary series who previously received only 1 dose of MenACWY, should get a 2nd dose of MenACWY as soon as feasible; forecast for the booster dose (if applicable) from the date of the 2nd primary series dose
• Persons aged 56 years or older who have never received a meningococcal vaccine and anticipate needing only one dose, MPSV4 (meningococcal polysaccharide vaccine) is preferred
• Persons who inadvertently receive MPSV4 should be revaccinated with MenACWY using a minimum interval of 8 weeks
• Meningococcal B (MenB) vaccines are discussed in a separate Quick Look posted at www.michigan.gov/immunize
• MenACWY Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
• Document Menactra as “MCV4 (Menactra)” and Menveo as “MCV4 (Menveo)” in MCIR
• Document as MenACWY (Menactra) or MenACWY (Menveo) on immunization record card and/or chart or EMR
• Use the lot number on the outside box of Menveo to document in MCIR and on the vaccine record

1 If MenACWY is given at age 10 years, will count as the age 11-12 years/1st dose of the adolescent series; give next dose at age 16 years
2 Recommended interval is 3-5 years but if unlikely to return at later date, give 2nd dose at age 16 years and at least 8 weeks after last dose
3 PCV13 = Pneumococcal Conjugate Vaccine; ensure at least one dose of PCV13 (Prevnar13®) is given to all persons with asplenia
4 For persons aged 2 years or older with asplenia, give the PCV13 dose 1st and wait 4 weeks before giving Menactra (MenACWY-D). Menveo (MenACWY-CRM) may be given at the same time or at any interval before/after PCV13.